Equisulin R 40IU Injection contains human insulin at a concentration of 40 international units (IU) per milliliter and is indicated for the management of diabetes mellitus requiring insulin therapy. This rapid-acting insulin formulation facilitates the regulation of blood glucose levels by promoting cellular glucose uptake and utilization, thereby reducing hyperglycemia. Equisulin R is typically administered subcutaneously to control postprandial blood glucose spikes and is essential in both type 1 and insulin-dependent type 2 diabetes patients. The onset of action generally occurs within 30 minutes, with peak effects observed between 2 to 4 hours and a duration of activity lasting approximately 6 to 8 hours. Dosage and administration should be individualized based on patient-specific glycemic response, dietary intake, and physical activity levels, with careful monitoring to minimize the risk of hypoglycemia. Equisulin R 40IU Injection must be used under medical supervision, and patients should be educated on proper injection techniques, storage conditions, and recognition of adverse effects such as hypoglycemia, allergic reactions, or lipodystrophy at the injection site. This product is contraindicated in patients with hypoglycemia or hypersensitivity to human insulin or any excipients. Regular blood glucose monitoring and periodic assessment of glycemic control are essential to optimize therapeutic outcomes.